Respiratory syncytial virus (RSV) immunisation
Up to date recommendations, vaccine schedules and resources on RSV (Respiratory syncytial virus) for immunisation providers.
www.health.vic.gov.auHere’s the latest overview on RSV vaccines in Australia based on recent reporting up to 2024–2025.
-
Australia granted the first-ever RSV vaccine approval for older adults: AREXVY (GSK) was approved by the Therapeutic Goods Administration (TGA) for adults 60 years and older, marking Australia’s first RSV vaccine approval. This approval aligned with similar approvals already in the UK, EU, US, and other regions, and positioned Australia to begin offering the vaccine to eligible seniors. A key note from the announcement was that the vaccine is given as a single dose and aims to reduce lower respiratory tract disease caused by RSV in older adults.[3]
-
Maternal RSV vaccination program and infant protection: Australia announced plans to add an RSV vaccine (Abrysvo) to national programs with a focus on vaccinating pregnant people to protect newborns. The rollout was anticipated in 2025 to help protect infants during winter, and the investment included funding to provide free vaccines for pregnant people nationwide. This approach complements other RSV prevention strategies by aiming to shield infants in the early months of life.[2]
-
Access and rollout status by state: At times, access to RSV vaccines in Australia has varied by location and program status. Some coverage and rollout details have been discussed in state-level health channels, with official guidance and immunisation resources updated to reflect new vaccines and schedules (examples include state health department pages and professional bodies).[4][7]
-
Public health context and safety: The approvals noted strong safety and efficacy profiles from large international trials, with health professionals emphasizing the potential to reduce hospitalizations and severe disease in older adults and in pregnancy-related protection for newborns. Immunisation groups in Australia welcomed the approvals as a meaningful public health step.[7][3]
Illustrative takeaways:
- AREXVY is Australia’s first RSV vaccine approval for 60+ adults, offering a single-dose option to reduce RSV-related lower respiratory tract disease.[3]
- A maternal RSV vaccination strategy (Abrysvo) was planned to ensure infant protection, with a 2025 rollout and free vaccines for pregnant people in some programs.[2]
- Access and timing can vary by state and program, so checking with local health departments or vaccination providers is advised for the latest availability and eligibility in your area.[4]
If you’d like, I can pull the most current state-by-state rollout status and eligibility details for your location (Valletta, Valletta, MT is in Malta, not Australia—if you meant Australia, please confirm the city/state you’re interested in). I can also summarize recent official guidance from Australian health agencies or provide a concise timeline of key approvals and rollout milestones.
Citations:
- AREXVY approval for Australians 60+.[3]
- Maternal RSV vaccine Abrysvo planned rollout and funding for pregnant people.[2]
- General RSV immunisation resources and safety discussions in Australia.[7][4]